Memphasys FCF Yield

What does Memphasys do? Memphasys Ltd, listed on the Australian Securities Exchange under the ticker MEM.AX, is a life sciences company headquartered in Homebush West, New South Wales. The company went public via an IPO on May 14, 2007. Memphasys operates within the Health Care sector, specifically in the Life Sciences Tools & Services industry. The company focuses on developing medical devices, diagnostics, and media for applications in assisted reproduction technology (ART) for both humans and animals. Its product pipeline includes several developments, such as Felix, ROSA, and AI-Port. Felix is a patented, automated device designed to separate high-quality sperm from semen for human in vitro fertilization (IVF) procedures, aiming to avoid DNA damage. ROSA functions as an in vitro diagnostic tool to evaluate semen and blood samples for oxidative stress. AI-Port is a system for storing and transporting animal semen for artificial insemination (AI) in livestock, capable of maintaining semen viability for up to four days without freezing, which is a common practice in standard AI procedures. The company's products target global markets, particularly in the field of reproductive biotechnology, with specific applications in both human and animal reproductive health. Memphasys operates with a focus on innovation in reproductive technology, leveraging proprietary media and diagnostic tools to address challenges in assisted reproduction. Memphasys is one of the most popular companies on Eulerpool.